On July 28, Procter & Gamble rose 3.04% in regular trading, trading at $152.5/share, with turnover of $250 million. The stock advanced as the market positioned ahead of the company's fiscal Q4 earnings release scheduled for the following day pre-market.

On the news front, Barclays recently raised its price target on Procter & Gamble from $146 to $152, maintaining an Equalweight rating. JPMorgan maintains an Overweight rating with a $162 target. According to FactSet, the analyst consensus rating is Overweight with an average target price of $162.95. UBS expects Q4 organic sales growth to slow to 1.4%, slightly below the Wall Street estimate of 1.7%, but projects fiscal 2027 organic growth of 3%, above the Street consensus of 2.5%.

The broader consumer staples sector showed strength, with Colgate-Palmolive up 2.89%, Kimberly-Clark up 2.75%, Clorox up 2.57%, and Church & Dwight up 2.12%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)